New study on tumour targeting platinum polymer by Access
Access Pharmaceuticals, of Dallas, US, is starting a new clinical study involving its DACH platinum polymer therapeutic, AP5346, for cancer treatment.
Access Pharmaceuticals, of Dallas, US, is starting a new clinical study involving its DACH platinum polymer therapeutic, AP5346, for cancer treatment.
The study will be conducted at the Moores Cancer Center at the University of California, San Diego in patients with head and neck cancer under a physician-sponsored IND. The company hopes to demonstrate the ability of the tumour-targeting polymer system to deliver more platinum to tumours than can be attained with oxaliplatin, the approved DACH platinum compound.
David Nowotnik, senior vice-president, r&d at Access, said: 'The effectiveness of platinum drugs is believed to increase as more platinum is delivered to the DNA of tumour cells. In preclinical studies, we have demonstrated that AP5346 delivers greater than 10-fold more platinum to the tumour DNA than is achieved by oxaliplatin. The clinical study is designed to provide us with valuable information on the effectiveness of our delivery system in man.'
This clinical study follows a phase I study in Europe, which demonstrated that AP5346 is well-tolerated, and is active.